Encyclopedia of Clinical Neuropsychology

2018 Edition
| Editors: Jeffrey S. Kreutzer, John DeLuca, Bruce Caplan

Corticobasal Degeneration

  • Alexander I. TrösterEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-57111-9_523

Synonyms

Corticobasal syndrome; Corticodentatonigral degeneration with neuronal achromasia

Short Description or Definition

First described as corticodentatonigral degeneration with neuronal achromasia by Rebeiz et al. in 1968, corticobasal degeneration (CBD) was long thought to be predominantly a motor disorder. Indeed, the original description of the disorder emphasized the relative preservation of mental faculties. More recently, emphasis has been placed on the neurobehavioral features of CBD, and the overlapping clinical and neuropathological features of CBD with frontotemporal lobar degenerations continue to generate debate about the classification and nosology of the disorder.

The motor presentation of CBD most often involves an asymmetric, progressive, akinetic-rigid parkinsonism of gradual onset that responds minimally if at all to levodopa and is sometimes accompanied by dystonia or myoclonus. Cortical signs that are common in CBD include asymmetric apraxia, cortical sensory...

This is a preview of subscription content, log in to check access.

References and Readings

  1. Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., Josephs, K. A., Kertesz, A., Lee, S. E., Miller, B. L., Reich, S. G., Riley, D. E., Tolosa, E., Tröster, A. I., Vidailhet, M., & Weiner, W. J. (2013). Criteria for the diagnosis of corticobasal degeneration. Neurology, 80, 496–503.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Boeve, B. F. (2007). Parkinson-related dementias. Neurologic Clinics, 25, 761–781.PubMedCrossRefPubMedCentralGoogle Scholar
  3. Geda, Y. E., Boeve, B. F., Negash, S., Graff-Radford, N. R., Knopman, D. S., Parisi, J. E., et al. (2007). Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration. Journal of Neuropsychiatry and Clinical Neurosciences, 19, 77–80.PubMedCrossRefPubMedCentralGoogle Scholar
  4. Graham, N. L., Bak, T. H., & Hodges, J. R. (2003). Corticobasal degeneration as a cognitive disorder. Movement Disorders, 18, 1224–1232.PubMedCrossRefPubMedCentralGoogle Scholar
  5. Litvan, I., Cummings, J. L., & Mega, M. (1998). Neuropsychiatric features of corticobasal degeneration. Journal of Neurology, Neurosurgery, and Psychiatry, 65, 717–721.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Marsili, L., Suppa, A., Berardelli, A., & Colosimo, C. (2016). Therapeutic interventions in parkinsonism: Corticobasal degeneration. Parkinsonism and Related Disorders, 22(Suppl. 1), S96–S100.PubMedCrossRefPubMedCentralGoogle Scholar
  7. Murray, R., Neumann, M., Forman, M. S., Farmer, J., Massimo, L., Rice, A., et al. (2007). Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology, 68, 1274–1283.PubMedCrossRefPubMedCentralGoogle Scholar
  8. Sha, S., Hou, C., Viskontas, I. V., & Miller, B. L. (2006). Are frontotemporal lobar degeneration, progressive supranuclear palsy and corticobasal degeneration distinct diseases? Nature Clinical Practice Neurology, 2, 658–665.PubMedCrossRefPubMedCentralGoogle Scholar
  9. Stamelou, M., & Bhatia, K. P. (2015). Atypical parkinsonism. Neurologic Clinics, 33, 39–56.PubMedCrossRefPubMedCentralGoogle Scholar
  10. Tröster, A. I., & Garrett, R. (2018). Parkinson’s disease and other movement disorders. In J. E. Morgan & J. H. Ricker (Eds.), Textbook of clinical neuropsychology (2nd ed.) (pp. 507–559). New York: Psychology Press.Google Scholar
  11. Tröster, A. I. (Ed.). (2015). Clinical neuropsychology and cognitive neurology of Parkinson’s disease and other movement disorders. New York: Oxford University Press.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Clinical Neuropsychology and Center for NeuromodulationBarrow Neurological InstitutePhoenixUSA